Monopar Therapeutics vs Rallybio
MNPR and RLYB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MNPR and RLYB compare
Monopar Therapeutics is the larger company, worth 5.8 times as much as Rallybio ($477M against $82.3M).
Rallybio scores higher on the StockData Score (10 against 7 for Monopar Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MNPR | RLYB |
|---|---|---|
| Size and price | ||
| Market cap | $477M | $82.3M |
| Share price | $71.06 | $15.29 |
| Change, 1 year | −8.9% | 199% |
| Change, 5 years | 193% | −85.5% |
| Beta (5Y) | 0.68 | 0.01 |
| Employees | 22 | 14 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 | 2 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 3.4× |
| P/S | – | 190× |
| P/B | 3.6× | 0.9× (better) |
| Growth | ||
| Revenue growth (TTM) | – | −35.6% |
| Profitability | ||
| Operating margin | – | −5581% |
| Net margin | – | 6177% |
| Return on equity | −19.5% | 34.5% (better) |
| Return on invested capital | – | −718% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 33.56 (better) | 28.87 |
| Altman Z-score | 68.99 (better) | 11.42 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.7% | – |
| Held by insiders | – | 72.6% |
| Insider net buying, 12 months | −$5.6M | $4.2M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 2.6% |
Go deeper
- MNPR stock overview
- MNPR income statement
- MNPR valuation and score
- RLYB stock overview
- RLYB income statement
- RLYB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.